Matrix metalloproteases: Underutilized targets for drug delivery

被引:117
作者
Vartak, Deepali G.
Gemeinhart, Richard A.
机构
[1] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA
关键词
drug delivery; drug targeting; matrix metalloprotease (MMP); prodrug; drug activation;
D O I
10.1080/10611860600968967
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pathophysiological molecules in the extracellular environment offer excellent targets that can be exploited for designing drug targeting systems. Matrix metalloproteases (MMPs) are a family of extracellular proteolytic enzymes that are characterized by their overexpression or overactivity in several pathologies. Over the last two decades, the MMP literature reveals heightened interest in the research involving MMP biology, pathology and targeting. This review describes various strategies that have been designed to utilize MMPs for targeting therapeutic entities. Key factors that need to be considered in the successful design of such systems have been identified based on the analyses of these strategies. Development of targeted drug delivery using MMPs has been steadily pursued; however, drug delivery efforts using these targets need to be intensified and focused to realize the clinical application of the fast developing fundamental MMP research.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 171 条
[1]   Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease [J].
Adair, JC ;
Charlie, J ;
Dencoff, JE ;
Kaye, JA ;
Quinn, JF ;
Camicioli, RM ;
Stetler-Stevenson, WG ;
Rosenberg, GA .
STROKE, 2004, 35 (06) :E159-E162
[2]   Matrix metalloproteinases/tissue inhibitors of metalloproteinases - Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease [J].
Ahmed, SH ;
Clark, LL ;
Pennington, WR ;
Webb, CS ;
Bonnema, DD ;
Leonardi, AH ;
McClure, CD ;
Spinale, FG ;
Zile, MR .
CIRCULATION, 2006, 113 (17) :2089-2096
[3]   Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].
Albright, CF ;
Graciani, N ;
Han, W ;
Yue, E ;
Stein, R ;
Lai, ZH ;
Diamond, M ;
Dowling, R ;
Grimminger, L ;
Zhang, SY ;
Behrens, D ;
Musselman, A ;
Bruckner, R ;
Zhang, MZ ;
Jiang, X ;
Hu, D ;
Higley, A ;
DiMeo, S ;
Rafalski, M ;
Mandlekar, S ;
Car, B ;
Yeleswaram, S ;
Stern, A ;
Copeland, RA ;
Combs, A ;
Seitz, SP ;
Trainor, GL ;
Taub, R ;
Huang, P ;
Oliff, A .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760
[4]   Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas [J].
Allen, C ;
McDonald, C ;
Giannini, C ;
Peng, KW ;
Rosales, G ;
Russell, SJ ;
Galanis, E .
JOURNAL OF GENE MEDICINE, 2004, 6 (11) :1216-1227
[5]  
Bae M, 2003, DRUG EXP CLIN RES, V29, P15
[6]  
BENJAMIN AB, 2004, Patent No. 20040228831
[7]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[8]   Conformational variability of matrix metalloproteinases: Beyond a single 3D structure [J].
Bertini, I ;
Calderone, V ;
Cosenza, M ;
Fragai, M ;
Lee, YM ;
Luchinat, C ;
Mangani, S ;
Terni, B ;
Turano, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5334-5339
[9]   Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases [J].
Bode, W ;
Maskos, K .
BIOLOGICAL CHEMISTRY, 2003, 384 (06) :863-872
[10]  
BOEHRINGER INGELHEIM, 2005, Patent No. 6855689